Immuneering (NASDAQ:IMRX - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at Chardan Capital in a research note issued to investors on Monday,Benzinga reports. They presently have a $13.00 price target on the stock. Chardan Capital also issued estimates for Immuneering's FY2025 earnings at ($1.65) EPS.
A number of other research analysts have also recently commented on the company. Morgan Stanley cut Immuneering from an "equal weight" rating to an "underweight" rating in a research note on Friday, December 13th. Needham & Company LLC reissued a "buy" rating and set a $12.00 target price on shares of Immuneering in a research note on Friday, March 21st.
Read Our Latest Analysis on IMRX
Immuneering Price Performance
Shares of IMRX stock traded down $0.02 during trading on Monday, hitting $1.64. 85,313 shares of the stock traded hands, compared to its average volume of 2,378,948. Immuneering has a 52-week low of $1.00 and a 52-week high of $3.83. The firm has a market capitalization of $58.85 million, a P/E ratio of -0.83 and a beta of -0.32. The firm's fifty day moving average price is $1.76 and its 200-day moving average price is $2.00.
Immuneering (NASDAQ:IMRX - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.16). As a group, equities research analysts expect that Immuneering will post -1.86 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. Corsair Capital Management L.P. acquired a new stake in shares of Immuneering in the 3rd quarter valued at $25,000. Tang Capital Management LLC purchased a new stake in Immuneering during the 4th quarter worth about $27,000. Marshall Wace LLP acquired a new position in shares of Immuneering during the 4th quarter worth about $47,000. First Manhattan CO. LLC. purchased a new position in shares of Immuneering in the 4th quarter valued at about $71,000. Finally, XTX Topco Ltd raised its position in shares of Immuneering by 177.2% during the 4th quarter. XTX Topco Ltd now owns 32,650 shares of the company's stock worth $72,000 after acquiring an additional 20,871 shares in the last quarter. Hedge funds and other institutional investors own 67.65% of the company's stock.
About Immuneering
(
Get Free Report)
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Read More
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
